Home > Boards > US Listed > Biotechs > Autolus Therapeutics plc (AUTL)

A new(ish) paper https://www.nature.com/articles/s41591-019-0549-5

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
jondoeuk Member Profile
 
Followed By 18
Posts 1,276
Boards Moderated 1
Alias Born 10/24/15
160x600 placeholder
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 1/8/2021 4:16:40 PM
Autolus Therapeutics provides business outlook for 2021 & 2022 GlobeNewswire Inc. - 1/6/2021 4:07:15 AM
Autolus Therapeutics to participate in Investor Conferences through January GlobeNewswire Inc. - 1/4/2021 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/7/2020 4:02:13 PM
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the 62nd ASH Annual Meeting GlobeNewswire Inc. - 12/7/2020 12:01:00 PM
Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) dur... GlobeNewswire Inc. - 12/5/2020 3:01:00 PM
Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medi... GlobeNewswire Inc. - 11/30/2020 7:00:00 AM
Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in ... GlobeNewswire Inc. - 11/17/2020 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/5/2020 4:04:54 PM
Autolus Therapeutics Reports Third Quarter 2020 Financial Results and Operational Progress GlobeNewswire Inc. - 11/5/2020 7:00:00 AM
Autolus Therapeutics to Report Third Quarter 2020 Financial Results and Host Conference Call on November 5 GlobeNewswire Inc. - 10/30/2020 7:00:10 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/18/2020 8:01:56 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/18/2020 7:12:50 AM
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020 GlobeNewswire Inc. - 9/18/2020 3:05:10 AM
Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking c... GlobeNewswire Inc. - 9/8/2020 7:00:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/27/2020 6:04:02 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 8/13/2020 4:10:04 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/6/2020 4:07:57 PM
Autolus Therapeutics Reports Second Quarter 2020 Financial Results and Operational Progress GlobeNewswire Inc. - 8/6/2020 7:00:10 AM
Autolus announces changes to its Board and Management Team GlobeNewswire Inc. - 8/4/2020 7:00:10 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 8/3/2020 4:13:33 PM
Autolus Therapeutics to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6 GlobeNewswire Inc. - 7/30/2020 7:00:10 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 7/20/2020 4:10:57 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 7/6/2020 4:16:26 PM
Amended Annual and Transition Report (foreign Private Issuer) (20-f/a) Edgar (US Regulatory) - 6/30/2020 4:14:54 PM
jondoeuk   Thursday, 10/24/19 04:49:00 PM
Re: None
Post # of 19 
A new(ish) paper https://www.nature.com/articles/s41591-019-0549-5

It was an open label, PhI trial, and 17 patients (under the age of 25) with advanced, high-risk CD19+ ALL were enrolled. Fourteen patients received lymphodepletion followed by the infusion of CAR T-cells (the product couldn't be generated for the remaining three).

Thirteen out of 14 patients developed cytokine release syndrome, which was generally mild (nine patients with Gr1, and four with Gr2). No severe (Gr3 or above) CRS was observed. Six had Gr1/2 neurotoxicity and one experienced Gr4 encephalopathy. One developed prolonged neutropenia, multiple infections, and Gr4 encephalopathy, and died from sepsis while in remission. Thirteen out of 14 patients developed prolonged B-cell aplasia.

At 30 days post infusion, 10 achieved a complete response. At 90 days, 12 of 14 had achieved a CR, one was alive with CD19+ disease, and one died due to progression of CD19+ disease. Six who achieved CR ultimately relapsed: 5 with CD19- and 1 with CD19+. In cases of CD19+ relapse/non-responding disease, anti-CAR-specific cytotoxic responses were detected, suggesting endogenous T-cell mediated rejection of CAR T-cells (not good). At a median follow-up of 14 months, 5 out of 14 (36%) patients remained in CR. Overall survival was 84% at 6 months and 63% at 12 months. Event-free survival was 63% and 46% at 6 and 12 months, respectively.

CAR T-cells exhibited mostly naive or central memory phenotypes and had a low level expression of PD-1 and TIM3. CAR T-cells underwent robust expansion in the periphery in 12 out of 14 patients, with a median time to peak expansion of 14 days. At peak expansion, a median of 41% of circulating T-cells were CAR T-cells. CAR T-cells contracted over time, but remained detectable in 11 out of 14 patients at last follow-up (up to 24 months for some patients). The median duration of persistence of CAR T-cells at data cutoff was 215 days. Peak expansion, exposure, persistence, and half-life were all higher than published data for an approved product.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences